That’s why I said it probably depends on whether Berlin has other irons in the fire. I would hope they wouldn’t consider an offering in lieu of a HOT deal simply to wait for NEO data. They don’t have to license the entire HOT now, but let’s be reasonable.
Sell the manufacturing plant to AMGN and let them pay for the staffing. No one with top biotech manufacturing skills will want to work for a floundering penny stock company.